![AveXis Reports Topline Results from Phase 1 Trial of SMA Type 1 Gene Therapy - Drug Discovery and Development AveXis Reports Topline Results from Phase 1 Trial of SMA Type 1 Gene Therapy - Drug Discovery and Development](https://drugdiscoverytrends.com/wp-content/uploads/2019/10/ddd1610_gene_therapy.jpg)
AveXis Reports Topline Results from Phase 1 Trial of SMA Type 1 Gene Therapy - Drug Discovery and Development
![AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha](https://static.seekingalpha.com/uploads/2016/11/40228756_14793455788213_rId128.png)
AveXis's House Of Cards: Dubious Trials, Drug Lawsuit And Fraud Allegations - Strong Sell With 94% Downside (NASDAQ:AVXS) | Seeking Alpha
![AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA](https://www.treatsma.uk/wp-content/uploads/2017/09/avxs-101.png)
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
![AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA](https://www.treatsma.uk/wp-content/uploads/2019/04/str1ve-data-table.png)
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy – TreatSMA
![AveXis Doubles Down, Adding 200 Jobs, $60M to Durham Gene Therapy Facility | North Carolina Biotechnology Center AveXis Doubles Down, Adding 200 Jobs, $60M to Durham Gene Therapy Facility | North Carolina Biotechnology Center](https://www.ncbiotech.org/sites/default/files/inline-images/Avexis%20scrngrab-logo_450px.png)
AveXis Doubles Down, Adding 200 Jobs, $60M to Durham Gene Therapy Facility | North Carolina Biotechnology Center
![AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age - Cure SMA AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age - Cure SMA](https://www.curesma.org/wp-content/uploads/2019/07/zolgensma-approval-graphic.jpg)